Literature DB >> 29113250

Comparison of miRNA and gene expression profiles between metastatic and primary prostate cancer.

Kaimin Guo1, Zuowen Liang1, Fubiao Li1, Hongliang Wang1.   

Abstract

The present study aimed to identify the regulatory mechanisms associated with the metastasis of prostate cancer (PC). The microRNA (miRNA/miR) microarray dataset GSE21036 and gene transcript dataset GSE21034 were downloaded from the Gene Expression Omnibus database. Following pre-processing, differentially expressed miRNAs (DEMs) and differentially expressed genes (DEGs) between samples from patients with primary prostate cancer (PPC) and metastatic prostate cancer (MPC) with |log2 fold change (FC)| >1 and a false discovery rate <0.05 were selected using the Linear Models for Microarray and RNA-seq Data 4 package of R. Next, a DEM-DEG regulatory network was constructed by downloading miRNA-DEG pairs from the miRNA.org database. Finally, functional annotation of each DEM-DEG module was performed using the Database for Annotation, Visualization and Integrated Discovery based on the Gene Ontology database. The upregulated miRNAs, including miR-144, miR-494 and miR-181a, exhibited a higher degree of connections compared with other nodes, including in the DEM-DEG regulatory network, and regulated a number of downregulated DEGs. According to the functional annotation of the DEM-DEG modules, miR-144 and its targeted DEGs enriched the highest number of biological process terms (36 terms), followed by miR-494 (24 terms), miR-30d (18 terms), miR-181a (15 terms), hsa-miR-196a (8 terms), miR-708 (7 terms) and miR-486-5p (2 terms). Therefore, these miRNAs may serve roles in the metastasis of PC cells via downregulation of their corresponding target DEGs.

Entities:  

Keywords:  DEM-DEG regulatory network; differentially expressed genes; metastatic prostate cancer; microRNA

Year:  2017        PMID: 29113250      PMCID: PMC5661486          DOI: 10.3892/ol.2017.6969

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

2.  Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate.

Authors:  S Uckert; A Küthe; U Jonas; C G Stief
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library.

Authors:  Pedro López-Romero
Journal:  BMC Genomics       Date:  2011-01-26       Impact factor: 3.969

5.  Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Authors:  Justin Guinney; Tao Wang; Teemu D Laajala; Kimberly Kanigel Winner; J Christopher Bare; Elias Chaibub Neto; Suleiman A Khan; Gopal Peddinti; Antti Airola; Tapio Pahikkala; Tuomas Mirtti; Thomas Yu; Brian M Bot; Liji Shen; Kald Abdallah; Thea Norman; Stephen Friend; Gustavo Stolovitzky; Howard Soule; Christopher J Sweeney; Charles J Ryan; Howard I Scher; Oliver Sartor; Yang Xie; Tero Aittokallio; Fang Liz Zhou; James C Costello
Journal:  Lancet Oncol       Date:  2016-11-16       Impact factor: 41.316

Review 6.  MicroRNAs in cancer: small molecules with a huge impact.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

7.  Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands.

Authors:  M J Wilson; A R Ruhland; B J Quast; P K Reddy; S L Ewing; A A Sinha
Journal:  J Androl       Date:  2000 Mar-Apr

8.  Aberrant HOXC expression accompanies the malignant phenotype in human prostate.

Authors:  Gary J Miller; Heidi L Miller; Adrie van Bokhoven; James R Lambert; Priya N Werahera; Osvaldo Schirripa; M Scott Lucia; Steven K Nordeen
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

9.  Identification of miR-30d as a novel prognostic maker of prostate cancer.

Authors:  Naohito Kobayashi; Hiroji Uemura; Kiyotaka Nagahama; Koji Okudela; Mitsuko Furuya; Yoko Ino; Yusuke Ito; Hisashi Hirano; Yoshiaki Inayama; Ichiro Aoki; Yoji Nagashima; Yoshinobu Kubota; Hitoshi Ishiguro
Journal:  Oncotarget       Date:  2012-11

10.  miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.

Authors:  S-F Su; Y-W Chang; C Andreu-Vieyra; J Y Fang; Z Yang; B Han; A S Lee; G Liang
Journal:  Oncogene       Date:  2012-10-22       Impact factor: 9.867

View more
  5 in total

1.  Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.

Authors:  Alicia C McDonald; Manish Vira; Vonn Walter; Jing Shen; Jay D Raman; Martin G Sanda; Dattatraya Patil; Emanuela Taioli
Journal:  Prostate       Date:  2019-04-08       Impact factor: 4.104

Review 2.  Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer.

Authors:  Matteo Giulietti; Matteo Santoni; Alessia Cimadamore; Francesco Carrozza; Francesco Piva; Liang Cheng; Antonio Lopez-Beltran; Marina Scarpelli; Nicola Battelli; Rodolfo Montironi
Journal:  Front Oncol       Date:  2018-06-13       Impact factor: 6.244

3.  A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature.

Authors:  Zhongwei Zhao; Sabine Weickmann; Monika Jung; Michael Lein; Ergin Kilic; Carsten Stephan; Andreas Erbersdobler; Annika Fendler; Klaus Jung
Journal:  Cancers (Basel)       Date:  2019-10-21       Impact factor: 6.639

4.  Discovery of extracellular vesicles derived miR-181a-5p in patient's serum as an indicator for bone-metastatic prostate cancer.

Authors:  Yanqing Wang; Yu-Xiang Fang; Baijun Dong; Xinxing Du; Jialin Wang; Xiao Wang; Wei-Qiang Gao; Wei Xue
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

5.  miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.

Authors:  Xiangjun Liu; Chengfeng Zhang; Cunhua Wang; Jianwei Sun; Deliang Wang; Yansheng Zhao; Xiaohui Xu
Journal:  Oncol Lett       Date:  2018-06-11       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.